image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 7.8
7.55 %
$ 37.7 M
Market Cap
-88.67
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one DXR stock under the worst case scenario is HIDDEN Compared to the current market price of 7.8 USD, Daxor Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one DXR stock under the base case scenario is HIDDEN Compared to the current market price of 7.8 USD, Daxor Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one DXR stock under the best case scenario is HIDDEN Compared to the current market price of 7.8 USD, Daxor Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DXR

image
$10.0$10.0$9.5$9.5$9.0$9.0$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
2.13 M REVENUE
1203.92%
536 K OPERATING INCOME
402.89%
536 K NET INCOME
91.11%
25.7 K OPERATING CASH FLOW
100.70%
0 INVESTING CASH FLOW
0.00%
-25.7 K FINANCING CASH FLOW
-0.70%
71.8 K REVENUE
-12.97%
-298 K OPERATING INCOME
29.42%
-1.63 M NET INCOME
-49.15%
-894 K OPERATING CASH FLOW
76.41%
1.04 M INVESTING CASH FLOW
-65.94%
894 K FINANCING CASH FLOW
14.16%
Balance Sheet Daxor Corporation
image
Current Assets 0
Cash & Short-Term Investments 0
Receivables 9.68 K
Other Current Assets -9.68 K
Non-Current Assets 0
Long-Term Investments 36.6 M
PP&E 0
Other Non-Current Assets -36.6 M
Infinity %Total Assets$0.0
Current Liabilities 0
Accounts Payable 0
Short-Term Debt 0
Other Current Liabilities 0
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
Total Liabilities$0.0
EFFICIENCY
Earnings Waterfall Daxor Corporation
image
Revenue 2.13 M
Cost Of Revenue 0
Gross Profit 2.13 M
Operating Expenses 1.59 M
Operating Income 536 K
Other Expenses 0
Net Income 536 K
3m3m2m2m2m2m1m1m500k500k002m02m(2m)536k0536kRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
25.17% OPERATING MARGIN
25.17%
25.17% NET MARGIN
25.17%
1.50% ROE
1.50%
1.46% ROA
1.46%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Daxor Corporation
image
20m20m15m15m10m10m5m5m00(5m)(5m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 536 K
Depreciation & Amortization 0
Capital Expenditures 0
Stock-Based Compensation 0
Change in Working Capital 14.1 K
Others -515 K
Free Cash Flow 25.7 K
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Daxor Corporation
image
DXR has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.03 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.080.080.070.070.060.060.050.050.040.040.030.030.020.020.010.010.000.000.030.040.070.030.030.00201520152016201620182018
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Daxor Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
50.1 K USD 2
0-3 MONTHS
0 USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will attend the 45th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions. This premier event gathers approximately 3,500 international specialists in advanced heart and lung disease treatment for four days of innovative research and knowledge exchange. globenewswire.com - 1 week ago
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025 WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation globenewswire.com - 2 weeks ago
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival Precise Volume Measurement Prior to Discharge Identifies Mortality Risk Oak Ridge, TN, April 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced compelling new data presented at the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. Research from The Minneapolis Heart Institute Foundation® and Allina Health Minneapolis Heart Institute® demonstrated that hospitalized heart failure patients who received blood volume analysis (BVA) prior to hospital discharge could be used to stratify those with a substantially better survival rate. globenewswire.com - 2 weeks ago
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation globenewswire.com - 1 month ago
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks Regional Medical Leaders Embrace Daxor's ezBVA Lab Service Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into three regional healthcare facilities across the U.S. These facilities will use Daxor's Tennessee-based ezBVA Lab, a CLIA-certified facility equipped with state-of-the-art technology. The ezBVA Lab delivers comprehensive blood volume analysis (BVA) results within 24 hours for both inpatient and outpatient settings, improving patient outcomes while reducing costs. globenewswire.com - 1 month ago
Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript Daxor Corporation (NASDAQ:DXR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Michael Feldschuh - Chief Executive Officer Bob Michel - Chief Financial Officer John Jefferies - Chief Medical Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Daxor Corporation Conference Call for the Corporate Update and Financial Results for the Year 2024. seekingalpha.com - 1 month ago
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. globenewswire.com - 1 month ago
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025 Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. globenewswire.com - 1 month ago
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 04, 2025 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw. globenewswire.com - 1 month ago
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. globenewswire.com - 1 month ago
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2023 versus $7.08 for the comparable period in 2023. globenewswire.com - 1 month ago
Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care Oak Ridge, TN, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into a leading Midwest healthcare facility. This 735-bed medical campus will integrate Daxor's blood volume analysis (BVA) testing into its outpatient care, enhancing precision in fluid management and patient outcomes. globenewswire.com - 2 months ago
8. Profile Summary

Daxor Corporation DXR

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 37.7 M
Dividend Yield 0.00%
Description Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Contact 109 Meco Lane, Oak Ridge, TN, 37830 https://www.daxor.com
IPO Date July 25, 1983
Employees 37
Officers Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. Chief Medical Officer Mr. Jonathan Adam Feldschuh Chief Scientific Officer & Director Mr. Michael Richard Feldschuh Chairman, President & Chief Executive Officer Ms. Kathryn A. Kornafel Senior Vice President of Marketing & Commercial Development Ms. Linda Cooper Vice President of Development & Operations Mr. Robert J. Michel CPA, CPA, M.B.A. Chief Financial Officer, Chief Compliance Officer & Corporate Secretary